News & Views

Press Releases

Phase 3 Results Show Population Council’s One-Year Contraceptive Vaginal System Highly Effective

Phase 3 Results Show Population Council’s One-Year Contraceptive Vaginal System Highly Effective
Photo credit: Population Council / Hallie Easley

NEW YORK, NEW YORK (June 20, 2019) – The Lancet Global Health today published results from the Phase 3 clinical efficacy trials of the Population Council-developed Annovera™ (segesterone acetate and ethinyl estradiol vaginal contraceptive system).  Annovera is the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control.  Results show that Annovera was 97% effective in preventing pregnancy for up to 13 menstrual cycles, which means that women do not need to return to the clinic or pharmacy for prescription refills.

Read more

Press Releases

New, multi-country study finds women who give birth before 18 are economically impacted for life

Vancouver, Thursday, June 6, 2019 – A new study, conducted by the Population Council and with Women Deliver, found a strong and consistent lifelong negative association between giving birth before age 18 and a woman’s economic empowerment. The research, previewed today at the Women Deliver 2019 Conference, the world’s largest conference on gender equality and the health, rights, and wellbeing of girls and women, points to the critical need to strengthen sexual and reproductive health and rights and expand economic opportunities for girls and women throughout their lives.

Read more

Press Releases

Biruh Tesfa to Scale-Up, Targeting Pivotal Population of Vulnerable Girls in Ethiopia

The Population Council and partners are expanding the implementation of Biruh Tesfa, an evidence-based program conceptualized by the Population Council to reduce the social isolation of vulnerable girls in urban Ethiopia, to reach girls living in forced domestic servitude, girls who are trafficked, as well as girls living with disabilities in Ethiopia.

Read more

Press Releases

First Trial Launches to Test Effectiveness of Male Contraceptive Gel

(November 28, 2018) NEW YORK, NY – The Population Council, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Los Angeles Biomedical Research Institute, and University of Washington School of Medicine today announced the launch of the first clinical trial to test the safety and efficacy of a gel for men to prevent unintended pregnancy. Three trial sites in the U.S. are now enrolling couples.

Read more

Press Releases

Population Council to Determine Feasibility of Fast-Tracking Oral Contraceptive Multipurpose Prevention Technology (cMPT) Development

NEW YORK, NEW YORK (November 14, 2018)  ̶  The Population Council has received initial funding from the Children’s Investment Fund Foundation (CIFF) to assess the feasibility of combining oral pre-exposure prophylaxis (PrEP) for HIV prevention with an oral contraceptive into a single pill, which women would take once a day.

Read more

Press Releases

The Population Council’s Régine Sitruk-Ware Named By TIME Magazine As One of 50 Most Influential People in Health Care of 2018

The Population Council’s Régine Sitruk-Ware Named By TIME Magazine As One of 50 Most Influential People in Health Care of 2018
Photo credit: TIME Magazine

New York, NY, 18 Oct. 2018 – Régine Sitruk-Ware, MD, distinguished scientist at the Population Council’s Center for Biomedical Research, has been named by TIME Magazine as one of the 50 Most Influential People in Health Care of 2018. Dr. Sitruk-Ware is being recognized for her research and leadership, which led to the recent U.S. FDA approval of Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control. 

Read more

Press Releases

New Research on Griffithisin and Carageenan to Prevent HIV and STIs Published in Nature Communications

September 24, 2018 – New research by the Population Council and partners shows that it may be possible to formulate a discreet, convenient, and woman-controlled multi-purpose technology to prevent HIV and other sexually transmitted infections (STIs) with limited risk of cross-resistance to antiretrovirals (ARV). This research published today in Nature Communications tests the non-antiretroviral agents, griffithsin (GRFT) and carrageenan (CG), in a fast-dissolving vaginal insert in rhesus macaques and mice.

Read more

Press Releases

FDA Approves the First One-Year Contraceptive Fully under a Woman’s Control

The Population Council, a global nonprofit research organization, announced it has received U.S. Food and Drug Administration (FDA) approval for Annovera™ (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive that provides an entire year of protection against unintended pregnancy while fully under a woman’s control. The approval marks an important step toward expanding contraceptive options for women.

Read more